Scholarlink

Background <p>Aberrant expression of lncRNA <i>CYP1B1-AS1</i> drives the pathogenesis of diverse cancers, with thyroid carcinoma (TC) being no exception.</p> Aim <p>This study was designed to clarify how <i>CYP1B1-AS1</i> expression impacts prognostic outcomes in TC patients.</p> Methods <p>qRT-PCR was employed to measure <i>CYP1B1-AS1</i> and miR-3127-5p expression signatures in TC tissues and cell lines. Prognostic value was analyzed by Kaplan-Meier survival and multivariate Cox regression assays. Binding affinities between <i>CYP1B1-AS1</i>/miR-3127-5p and miR-3127-5p/<i>ERBB2</i> were validated by dual-luciferase reporter assays; RNA pull-down assays were used to confirm the <i>CYP1B1-AS1</i>/miR-3127-5p interaction. Flow cytometry, CCK-8, Wound Healing and Transwell assays were employed to evaluate TC cell apoptosis, growth, motility and invasiveness, respectively. Western blot was performed to detect ERBB2 protein expression.</p> Results <p><i>CYP1B1-AS1</i> was significantly upregulated in TC tissues and cell lines, with concomitant downregulation of miR-3127-5p. TC patients with elevated <i>CYP1B1-AS1</i> expression exhibited markedly decreased survival rates. <i>CYP1B1-AS1</i>, TNM stage, local invasion, and LNM were defined as prognostic correlates for TC. Knockdown of <i>CYP1B1-AS1</i> inhibited the malignant phenotypic behaviors of TC cells. <i>CYP1B1-AS1</i> bound to miR-3127-5p, and the miR-3127-5p inhibitor could counteract the inhibitory effects induced by <i>CYP1B1-AS1</i> knockdown. <i>ERBB2</i> was identified as a downstream target gene of miR-3127-5p.</p> Conclusion <p>Increased <i>CYP1B1-AS1</i> expression correlates strongly with reduced overall survival in TC patients, establishing it as a clinically applicable prognostic indicator and promising therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Upregulation of CYP1B1-AS1 correlates with aggressive phenotypes and poor prognosis in thyroid cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月23日

查看全文
  • Xun Li,
  • Huiling Qin,
  • Xiaotao Duan,
  • Jike Wang,
  • Jiayong Zhang

摘要

Background

Aberrant expression of lncRNA CYP1B1-AS1 drives the pathogenesis of diverse cancers, with thyroid carcinoma (TC) being no exception.

Aim

This study was designed to clarify how CYP1B1-AS1 expression impacts prognostic outcomes in TC patients.

Methods

qRT-PCR was employed to measure CYP1B1-AS1 and miR-3127-5p expression signatures in TC tissues and cell lines. Prognostic value was analyzed by Kaplan-Meier survival and multivariate Cox regression assays. Binding affinities between CYP1B1-AS1/miR-3127-5p and miR-3127-5p/ERBB2 were validated by dual-luciferase reporter assays; RNA pull-down assays were used to confirm the CYP1B1-AS1/miR-3127-5p interaction. Flow cytometry, CCK-8, Wound Healing and Transwell assays were employed to evaluate TC cell apoptosis, growth, motility and invasiveness, respectively. Western blot was performed to detect ERBB2 protein expression.

Results

CYP1B1-AS1 was significantly upregulated in TC tissues and cell lines, with concomitant downregulation of miR-3127-5p. TC patients with elevated CYP1B1-AS1 expression exhibited markedly decreased survival rates. CYP1B1-AS1, TNM stage, local invasion, and LNM were defined as prognostic correlates for TC. Knockdown of CYP1B1-AS1 inhibited the malignant phenotypic behaviors of TC cells. CYP1B1-AS1 bound to miR-3127-5p, and the miR-3127-5p inhibitor could counteract the inhibitory effects induced by CYP1B1-AS1 knockdown. ERBB2 was identified as a downstream target gene of miR-3127-5p.

Conclusion

Increased CYP1B1-AS1 expression correlates strongly with reduced overall survival in TC patients, establishing it as a clinically applicable prognostic indicator and promising therapeutic target.